EPCORE FL-1: Epcoritamab plus lenalidomide and rituximab demonstrate consistent efficacy across high- and low-risk subgroups in R/R FL Lymphoma Share: Do you want to read an article? Please log in or register. E mail Password Login Register for Free Remember me Forgot password? Click here
Do you want to read an article? Please log in or register. E mail Password Login Register for Free Remember me
